Prashant Sharma, MD, FACP

Attending- Malignant Hem/ BMT/ Cellular Therapy @Intermountain, SLC, UT.

[Prashant Sharma, MD, FACP @psharmaMD]

@DocsDock200 Great! Great points. What’s your thought on use of PB as stem cell source?

[Luciano J Costa @End_myeloma]

We have now 3 CT with T-cell redirecting therapy vs. Triples in 1-3 prior LOT in MM with OS superiority. I don't consider acceptable to start randomized trials with DPd/Kd/EPd/etc control when we have proven superior "established therapy with clinical benefit". #mmsm

[Prashant Sharma, MD, FACP @psharmaMD]

@TMSchmidtMD @BijoyTelivala @OncBrothers @RahulBanerjeeMD @VincentRK @HadidiSamer What platform do you use for risk stratification btw? Most community and academic centers still use FISH. Is there a best commercially available MM sequencing (NGS) for risk stratification purpose? @VincentRK @rajshekharucms

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

An @US_FDA ODAC will be held May 20th to discuss the potential approval for Dara in smoldering myeloma #mmsm

Very good points made in the discussion 👇

➡️ https://t.co/5WlEaR7shQ

Few important observations summarised here🧵

[Prashant Sharma, MD, FACP @psharmaMD]

@CIBMTR @ASTCT Now that #Tandem25 is over, the virtual part— The virutal playform (which many paid for as a service) is pretty bad. Can not scroll, video freezes, platform is pretty poor and essentially doesnt work! @RahulBanerjeeMD is tech savvy- does it work for you?

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH24 #mmsm

Few important observations on AQUILA

This is in top of prior observations I shared

🧵

[Prashant Sharma, MD, FACP @psharmaMD]

@VincentRK @AaronGoodman33 @thanosdimop @NEJM I think it will take me more time/ thinking to apply AQUILA to pts. Not using antiCD38 for some MM pts, SLIM progression etc makes me take pause. Also if Dara is approved, I fear instantly relevance of Ecog DR vs R might get questioned. SMM discussion with pts is a complex one!

[Prashant Sharma, MD, FACP @psharmaMD]

@VincentRK @AaronGoodman33 @thanosdimop @NEJM Great insight, thx. I see MM pts everyday had practical Qs. Dr Rajkumar, when HRSMM pt progress on Dara or soon after to MM, what’s your rec for nextline? You’ve favored no Dara maint despite many doing for MM. Is 3yrsDara for SMM not equally finacially toxic to pt or healthcare?

[Prashant Sharma, MD, FACP @psharmaMD]

@AshKishtagari @SJMorrison_ @VUMC_Cancer @StephenChung16 @DrAdetolaKassim Wonderful lecture of course. Practically, Ashwin, are you routinely discontinuing nonselective beta blockers post stem cell infusion and not resuming until engraftment whenever possible?

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Anitocel presented 40 enrolled and 38 dosed. 100M cells. Prior LOT 5-4. ORR 100% 76% CR or better, across all groups. Median PFS not reached at 2 years. Not even in EMD group. No clear HR genetics influence ORR. No MNT. iMMagjne-3 trial similar to CARTITUDE-4
#IMS24RF #mmsm

[Jeffrey Matous, MD @MileHighMyeloma]

To all heme onc health care folks hope you can make this. Also MOC available. This weekend

[Prashant Sharma, MD, FACP @psharmaMD]

@ManniMD1 Great! A third column with duration of therapy and maintenance would be very helpful too! This part is a continuum afterall and patients frequently “ask how long do I need to be on (combination) treatment or maintenance.”

[Prashant Sharma, MD, FACP @psharmaMD]

@rajshekharucms @CAMPamyloidosis @abazarbachi @SLentzsch Any of these patient with t(11;14)?

[#MultipleMyelomaAwareness @Thatquaratined1]

Its mostly no different than donating blood, but South Asian Blood cancer patients needing donor marrow are far less likely to find a match than most other ethnic groups because we make up <3% of the NMDP registry. Please consider becoming a donor - just takes a cheek swab!

[Shematologist, MD @acweyand]

She believed she could but it was uncompensated, non promotable work she had no interest in so she set a reasonable boundary, protected her time, and said no.

[Prashant Sharma, MD, FACP @psharmaMD]

@zucenka @VU_LT Very important analysis in high risk patients. I have never used actinmycin or amsacrin and there was one patient who got FLAGIDAVen (applicable to the US). Are the these regimens common in the EU?

[Prashant Sharma, MD, FACP @psharmaMD]

@MM_Hub @rajshekharucms @ADispenzieri I/others taking care of SMM/ MM pts daily at ground level appreciate this discussion. I wish I could listen to the discussion. I fully agree the obvious over treatment & harm if all high-risk SMM pts were treated. This side of argument is shadowed by those who advocate treatment.

[Multiple Myeloma Hub @MM_Hub]

CONGRESS| #SOHO2023
In the smoldering MM: Time to Watch and Wait session @ADispenzieri debates how to treat patients with high-risk smoldering MM based on OS data that may have been contaminated with actual MM patients and if it is ethical to treat low and intermediate risk who only have a 50% chance of developing MM in 10 years.
#mmsm #soho23

[Prashant Sharma, MD, FACP @psharmaMD]

@Drjhoffmanmiami What is your thought on BB and cardiac amyloid-- do BBs increase adverse cardiac risks including risk of sudden cardiac death in cardiac amyloid patients?

[Prashant Sharma, MD, FACP @psharmaMD]

@bdermanmd Post BCMA CAR relapse, what is your overall though on sequencing? Tec —> Talq or goto Talq post BCMA CAR relapse? If so, where is the place for Tec?

And if pt not CAR candidate, wd you use Tec or Talq? @rajshekharucms @ManniMD1